Get intelligentvalue.com

Own it today or select a payment plan

Secured by Stripe

Premium Domain Name

intelligentvalue.com

intelligentvalue.com logo

is available for purchase

51 views
Visitors fromUSUS 54%·AUAU 32%·ININ 7%·GBGB 2%·FRFR 2%

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

VisaMastercardAmerican ExpressDiscoverDiners ClubJCBApple PayGoogle Pay

Is Cigna Group Stock Underperforming the Dow?

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Based in Bloomfield, Connecticut, The Cigna Group (CI) is a diversified health services leader that blends insurance with integrated care solutions. Through its Evernorth and Cigna Healthcare platforms, the company delivers pharmacy benefit management, medical and specialty coverage, Medicare plans, behavioral health services, and employer-focused risk protection products. 

With a market cap of nearly $76 billion, the company firmly resides in the “large-cap” tier reserved for businesses valued above $10 billion. The scale strengthens the company’s negotiating leverage with providers and pharmaceutical manufacturers while giving management flexibility to invest in innovation and targeted expansion.

 

Cigna’s shares are currently trading 17.5% below their 52-week high of $350 reached in May 2025. Over the past three months, however, the stock jumped 3.8%, slightly trailing the 4.4% gain recorded by the Dow Jones Industrial Average ($DOWI).

www.barchart.com

Over the past 52 weeks, CI stock underperformed the Dow Jones. Its shares declined 5.4% during that stretch, while the Dow advanced nearly 14%. The script shifted in 2026 as year-to-date (YTD) CI stock has gained 4.9%, outperforming the Dow’s 3% rise. 

From a technical standpoint, CI stock reclaimed its 50-day moving average in late December 2025 after briefly slipping below it in November. The stock has largely held above that level since, with the 50-day moving average now at $279.40, signaling firmer near-term momentum. 

However, shares continue to trade below the 200-day moving average of $291.33, a level that has capped upside since mid-2025.

www.barchart.com

Operational performance has added weight to the improving tone. On Feb. 5, shares rose 4.7% after Cigna reported fourth-quarter fiscal 2025 results. Revenue climbed 10.4% year over year to $72.5 billion, surpassing analyst expectations of $69.9 billion. Adjusted EPS grew 21.7% from the year-ago value to $8.08, exceeding the consensus estimate of $7.88.

Management credited the quarter’s performance to robust expansion in its EverNorth specialty and care services, successful adoption of biosimilars, and operational discipline across its health benefits business. 

Looking ahead, they project full-year 2026 consolidated adjusted revenue of approximately $280 billion. The company expects consolidated adjusted income from operations of at least $30.25 per share. Given earnings seasonality, first-quarter EPS could land slightly above 25% of full-year guidance.

To place performance in context, rival Centene Corporation (CNC) has fallen 24.6% over the past 52 weeks, though it has risen 4.3% YTD. The comparison highlights that the broader managed care landscape faced meaningful headwinds over the past year.

Despite uneven price action in recent months, Cigna Group continues to earn Wall Street’s confidence through consistent operational delivery. CI stock carries a “Strong Buy” consensus rating from 23 analysts, reflecting conviction in earnings durability and strategic execution.

The average price target of $336.18 implies 16.4% upside from current levels, signaling that analysts see room for multiple expansion as fundamentals hold firm.


On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.03
-7.76 (-3.06%)
AAPL  307.34
-3.89 (-1.25%)
AMD  466.38
-56.82 (-10.86%)
BAC  53.83
-0.06 (-0.11%)
GOOG  365.76
-3.51 (-0.95%)
META  593.00
-34.57 (-5.51%)
MSFT  416.67
-11.38 (-2.66%)
NVDA  205.10
-13.56 (-6.20%)
ORCL  213.68
-22.66 (-9.59%)
TSLA  391.00
-27.45 (-6.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.